BioCentury
ARTICLE | Top Story

Human CRISPR study clears NIH committee hurdle

June 22, 2016 12:15 AM UTC

NIH's Recombinant DNA Advisory Committee (RAC) voted in favor of a proposal from the University of Pennsylvania's Perelman School of Medicine to begin a clinical trial studying CRISPR/ Cas9 gene editing to treat cancer, the university said. The proposed study would be the first human use of CRISPR/Cas9 technology (see BioCentury Extra, June 17).

UPenn declined to provide additional details of the study protocol, titled "Phase I Trial of Autologous T cells Engineered to Express NYESO-1 TCR and Gene Edited to Eliminate Endogenous TCR and PD-1." SVP of Public Affairs Susan Phillips told BioCentury the university plans to present the proposal to FDA for review. ...